SEC Tracker
Get the app

Maze Therapeutics MAZE

On February 4, 2026, Maze Therapeutics, Inc. entered into

Form
8-K
Filed
Importance
Routine
  • Signs a material agreement (1.01)
  • Ends a material agreement (1.02)
  • Takes on a new financial obligation (2.03)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Maze Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Theravance Biopharma TBPH public float $449M, Jun 30, 2025
  2. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  3. aTYR PHARMA ATYR public float $464M, Jun 30, 2025
  4. Arvinas ARVN public float $469M, Jun 30, 2025
  5. CytoDyn CYDY public float $418M, Nov 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.